Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ESPR | 8-K | neutral | 3/10 | Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026 | Jun 5, 2026 |
| VALN | 6-K | neutral | 2/10 | Valneva filed a 6-K announcing the availability of documentation for its Annual General Meeting scheduled for June 25, 2 | Jun 5, 2026 |
| TKPHF | 6-K | bearish | 6/10 | Takeda revised its FY2025 consolidated financial statements to recognize a provision for legal proceedings following an | Jun 5, 2026 |
| TKPHF | 6-K | bearish | 6/10 | Takeda reported FY2025 (year ended March 31, 2026) results showing a net loss attributable to owners of JPY 152.4 billio | Jun 5, 2026 |
| SXTC | 424B5 | bearish | 7/10 | China SXT Pharmaceuticals filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $100 m | Jun 5, 2026 |
| ARVN | 8-K | bearish | 6/10 | Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for AR | Jun 5, 2026 |
| FBRX | S-3 | bearish | 6/10 | Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in sec | Jun 5, 2026 |
| CABA | 8-K | bullish | 7/10 | Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 202 | Jun 5, 2026 |
| RDPTF | 6-K | neutral | 2/10 | Radiopharm Theranostics filed a Form 6-K reporting the expiry of 505,598 unquoted options (RADAN) without exercise or co | Jun 5, 2026 |
| CUE | S-3 | bearish | 6/10 | Cue Biopharma filed an S-3 registration statement to register 4,090,908 shares of common stock for resale by selling sto | Jun 5, 2026 |
| XERS | 144 | neutral | 2/10 | Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock, with an estimated ag | Jun 5, 2026 |
| PCRX | DEFA14A | mixed | 6/10 | Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominee | Jun 5, 2026 |
| IQV | 8-K | neutral | 3/10 | IQVIA's subsidiary priced €950M in senior notes due 2033 at 4.625% to refinance existing debt. This is a routine refinan | Jun 5, 2026 |
| GNLX | CLUSTER | neutral | 2/10 | Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sales over a 7-day wind | Jun 4, 2026 |
| LQDA | 144 | bearish | 6/10 | Director Paul B. Manning filed a Form 144 on June 4, 2026, indicating intent to sell 200,000 shares of Liquidia Corp com | Jun 4, 2026 |
| SMMT | CLUSTER | bullish | 5/10 | Both co-CEOs and the COO/CFO of Summit Therapeutics made open-market purchases totaling $3.28M on June 4, 2026, at ~$14. | Jun 4, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Four NBIX C-suite insiders sold a total of $4.93M in open-market shares over a 7-day window, with the largest sales by t | Jun 4, 2026 |
| NBIX | CLUSTER | neutral | 2/10 | Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares within a 7-day window. Al | Jun 4, 2026 |
| SMMT | CLUSTER | bullish | 6/10 | Co-CEO Mahkam Zanganeh and COO/CFO Manmeet Singh collectively purchased $1.82M in open-market shares at ~$14.50 on June | Jun 4, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three top executives at United Therapeutics (CEO, CFO, General Counsel) collectively sold $1.11M in open-market shares o | Jun 4, 2026 |
| LQDA | 144 | bearish | 5/10 | Venture capital firm Canaan VIII LP, a director of Liquidia Corp, filed a Form 144 on June 4, 2026, indicating intent to | Jun 4, 2026 |
| NRXPW | 8-K | bearish | 6/10 | NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 p | Jun 4, 2026 |
| PACB | 8-K | neutral | 3/10 | Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive P | Jun 4, 2026 |
| ELOX | S-1/A | neutral | 5/10 | Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering of 2,730,000 shares | Jun 4, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22 | Jun 4, 2026 |
| ABPWW | 8-K | bearish | 8/10 | Abpro Holdings received final notification from the Nasdaq Listing and Hearing Review Council reaffirming the delisting | Jun 4, 2026 |
| JBIO | 8-K | bearish | 6/10 | Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, with an underwriter | Jun 4, 2026 |
| JBIO | 424B5 | bearish | 7/10 | Jade Biosciences priced a $150M underwritten public offering of 10M shares at $15.00/share (14.7% discount to the $17.59 | Jun 4, 2026 |
| LIXT | 8-K | bearish | 6/10 | Lixte Biotechnology closed a registered direct offering raising approximately $16.6 million in gross proceeds through th | Jun 4, 2026 |
| ALKS | CLUSTER | neutral | 3/10 | Three Alkermes insiders, including the EVP R&D/CMO and VP Finance, sold a total of ~$1.15M in open-market sales over a 7 | Jun 4, 2026 |